Von Hippel-Lindau syndrome: in vivo portrait with 68Ga-DOTANOC PET-CT

2017 ◽  
Author(s):  
Moreira Ana Paula ◽  
Gracinda Costa ◽  
de Lima Joao Pedroso
Keyword(s):  
Von Hippel Lindau ◽  
Pet Ct ◽  
Von Hippel Lindau Syndrome

scholarly journals Von Hippel-Lindau Syndrome: Demonstration of Entire Disease Spectrum with68Ga-DOTANOC PET-CT

2014 ◽  
Vol 15 (1) ◽  
pp. 169 ◽  
Author(s):  
Punit Sharma ◽  
Varun Singh Dhull ◽  
Chandrasekhar Bal ◽  
Arun Malhotra ◽  
Rakesh Kumar
Keyword(s):  
Von Hippel Lindau ◽  
Disease Spectrum ◽  
Pet Ct ◽  
Von Hippel Lindau Syndrome

FDG PET/CT Detects Clinically Occult Pancreatic Cancer in a Case of Von Hippel–Lindau Syndrome

2013 ◽  
Vol 38 (7) ◽  
pp. e302-e303 ◽  
Author(s):  
Mukta Kulkarni ◽  
Nilendu Purandare ◽  
Anand Zade ◽  
Archi Agrawal ◽  
Sneha Shah ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Fdg Pet ◽  
Von Hippel Lindau ◽  
Pet Ct ◽  
Fdg Pet Ct ◽  
Von Hippel Lindau Syndrome

[18F]FDG PET/CT in pancreatic neuroendocrine tumours associated with von Hippel Lindau Syndrome

2009 ◽  
Vol 70 (4) ◽  
pp. 657-659 ◽  
Author(s):  
John Kok ◽  
Michael Lin ◽  
Vincent Wong ◽  
Peter Campbell ◽  
Peter Lin
Keyword(s):  
Fdg Pet ◽  
Neuroendocrine Tumours ◽  
Von Hippel Lindau ◽  
Pet Ct ◽  
Pancreatic Neuroendocrine Tumours ◽  
18F Fdg ◽  
Fdg Pet Ct ◽  
Von Hippel Lindau Syndrome

In-vivo-Detektion des Betastrahlers Yttrium-90 im PET/CT nach Selektiver Interner Radiotherapie (SIRT) der Leber

2011 ◽  
Vol 183 (S 01) ◽  
Author(s):  
MK Werner ◽  
J Kupferschläger ◽  
K Brechtel ◽  
T Beyer ◽  
R Bares ◽  
...  
Keyword(s):  
Pet Ct ◽  
Yttrium 90

[18F]-florbetaben PET/CT Imaging in the Alzheimer’s Disease Mouse Model APPswe/PS1dE9

2018 ◽  
Vol 16 (1) ◽  
pp. 49-55 ◽  
Author(s):  
J. Stenzel ◽  
C. Rühlmann ◽  
T. Lindner ◽  
S. Polei ◽  
S. Teipel ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Mouse Model ◽  
New Drugs ◽  
Imaging Data ◽  
Wild Type ◽  
Preclinical Research ◽  
Standardized Uptake Values ◽  
Pet Ct

Background: Positron-emission-tomography (PET) using 18F labeled florbetaben allows noninvasive in vivo-assessment of amyloid-beta (Aβ), a pathological hallmark of Alzheimer’s disease (AD). In preclinical research, [<sup>18</sup>F]-florbetaben-PET has already been used to test the amyloid-lowering potential of new drugs, both in humans and in transgenic models of cerebral amyloidosis. The aim of this study was to characterize the spatial pattern of cerebral uptake of [<sup>18</sup>F]-florbetaben in the APPswe/ PS1dE9 mouse model of AD in comparison to histologically determined number and size of cerebral Aβ plaques. Methods: Both, APPswe/PS1dE9 and wild type mice at an age of 12 months were investigated by smallanimal PET/CT after intravenous injection of [<sup>18</sup>F]-florbetaben. High-resolution magnetic resonance imaging data were used for quantification of the PET data by volume of interest analysis. The standardized uptake values (SUVs) of [<sup>18</sup>F]-florbetaben in vivo as well as post mortem cerebral Aβ plaque load in cortex, hippocampus and cerebellum were analyzed. Results: Visual inspection and SUVs revealed an increased cerebral uptake of [<sup>18</sup>F]-florbetaben in APPswe/ PS1dE9 mice compared with wild type mice especially in the cortex, the hippocampus and the cerebellum. However, SUV ratios (SUVRs) relative to cerebellum revealed only significant differences in the hippocampus between the APPswe/PS1dE9 and wild type mice but not in cortex; this differential effect may reflect the lower plaque area in the cortex than in the hippocampus as found in the histological analysis. Conclusion: The findings suggest that histopathological characteristics of Aβ plaque size and spatial distribution can be depicted in vivo using [<sup>18</sup>F]-florbetaben in the APPswe/PS1dE9 mouse model.

scholarly journals Increased [18F]FMISO accumulation under hypoxia by multidrug-resistant protein 1 inhibitors

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Yoichi Shimizu ◽  
Yukihiro Nakai ◽  
Hiroyuki Watanabe ◽  
Shimpei Iikuni ◽  
Masahiro Ono ◽  
...  
Keyword(s):  
Cyclosporine A ◽  
Pet Imaging ◽  
Multidrug Resistant ◽  
Ct Images ◽  
Pet Scan ◽  
Reduced Form ◽  
Pet Ct ◽  
Fadu Cells ◽  
Hypoxic State

Abstract Background [18F]Fluoromisonidazole ([18F]FMISO) is a PET imaging probe widely used for the detection of hypoxia. We previously reported that [18F]FMISO is metabolized to the glutathione conjugate of the reduced form in hypoxic cells. In addition, we found that the [18F]FMISO uptake level varied depending on the cellular glutathione conjugation and excretion ability such as enzyme activity of glutathione-S-transferase and expression levels of multidrug resistance-associated protein 1 (MRP1, an efflux transporter), in addition to the cellular hypoxic state. In this study, we evaluated whether MRP1 activity affected [18F]FMISO PET imaging. Methods FaDu human pharyngeal squamous cell carcinoma cells were pretreated with MRP1 inhibitors (cyclosporine A, lapatinib, or MK-571) for 1 h, incubated with [18F]FMISO for 4 h under hypoxia, and their radioactivity was then measured. FaDu tumor-bearing mice were intravenously injected with [18F]FMISO, and PET/CT images were acquired at 4 h post-injection (1st PET scan). Two days later, the same mice were pretreated with MRP1 inhibitors (cyclosporine A, lapatinib, or MK-571) for 1 h, and PET/CT images were acquired (2nd PET scan). Results FaDu cells pretreated with MRP1 inhibitors exhibited significantly higher radioactivity than those without inhibitor treatment (cyclosporine A: 6.91 ± 0.27, lapatinib: 10.03 ± 0.47, MK-571: 10.15 ± 0.44%dose/mg protein, p < 0.01). In the in vivo PET study, the SUVmean ratio in tumors [calculated as after treatment (2nd PET scan)/before treatment of MRP1 inhibitors (1st PET scan)] of the mice treated with MRP1 inhibitors was significantly higher than those of control mice (cyclosporine A: 2.6 ± 0.7, lapatinib: 2.2 ± 0.7, MK-571: 2.2 ± 0.7, control: 1.2 ± 0.2, p < 0.05). Conclusion In this study, we revealed that MRP1 inhibitors increase [18F]FMISO accumulation in hypoxic cells. This suggests that [18F]FMISO-PET imaging is affected by MRP1 inhibitors independent of the hypoxic state.

VON HIPPEL–LINDAU SYNDROME

2020 ◽  
pp. 1005-1020
Author(s):  
Samantha E. Greenberg ◽  
Luke D. Maese ◽  
Benjamin L. Maughan
Keyword(s):  
Von Hippel Lindau ◽  
Von Hippel Lindau Syndrome
Sign in / Sign up

Export Citation Format

Share Document